Objectives. Moxifloxacin is not approved by the US Food and Drug Administration for pediatric use. Although its use might be indicated under certain conditions, data regarding its safety and tolerability in pediatric patients are limited. The primary objective of this study was to evaluate the safety of systemic moxifloxacin therapy in children.
Moxifloxacin is a fourth-generation fluoroquinolone approved by the US Food and Drug Administration (FDA) for treatment of specific bacterial infections in adults [1] . After the drug was approved by the FDA in 1999, postmarketing surveillance revealed various adverse effects attributed to its use [2] [3] [4] [5] [6] [7] [8] [9] [10] . The FDA subsequently issued a black-box warning regarding associations with spontaneous tendon rupture [11] and exacerbation of myasthenia gravis symptoms in adults [12] . In 2016, the FDA recommended against using fluoroquinolones as firstline agents for acute sinusitis, bronchitis, or uncomplicated urinary tract infection because of their potential serious adverse effects involving the musculoskeletal or nervous system [13] . Systemic use (via any route other than topical) of moxifloxacin in children is not currently approved by the FDA, but given the drug's high oral bioavailability, broad-spectrum coverage, and penetration of the central nervous system, it occupies a unique niche among pediatric treatment options. Important uses of moxifloxacin in the pediatric population include treatment and prophylaxis of multidrug-resistant tuberculosis [14] [15] [16] and treatment of other mycobacterial infections, atypical pneumonia [17] , and neonatal Mycoplasma hominis meningitis [18, 19] . In addition, because moxifloxacin is effective against many Gram-positive, Gram-negative, and anaerobic bacteria, it serves as an oral single-drug alternative to first-line therapies for polymicrobial infections.
Although moxifloxacin use in pediatric patients has been reported, data regarding its safety and tolerability in children are lacking. Since September 11, 2013, under our antimicrobial stewardship program (ASP), the use of moxifloxacin has been restricted in children <12 years of age, which means that a pediatric infectious disease (ID) consultation is required before using the drug in this age group. The main rationale for restricting moxifloxacin use was the lack of data on pediatric dosing and safety.
Our primary objective in this study was to evaluate the safety and tolerability of systemic moxifloxacin in children by determining the frequency and types of adverse events (AEs) that occurred during therapy over a several-year period. Our secondary objectives were to determine risk factors for moxifloxacin-associated AEs, investigate AE-monitoring practices at baseline and during therapy, and assess the effects of pediatric ID consultation on monitoring and use.
PATIENTS AND METHODS

Study Design
We performed a retrospective cohort study of patients who received moxifloxacin at Boston Children's Hospital, an approximately 400-bed acute-care freestanding children's hospital. This study was approved by the Boston Children's Hospital institutional review board with a waiver of informed consent.
Inclusion and Exclusion Criteria
All patients <18 years of age who were administered ≥1 dose of intravenous or oral moxifloxacin while hospitalized or in the emergency department (ED) between January 1, 2011, and July 31, 2016, were included. Patients whose initial moxifloxacin administration occurred in an outpatient setting were included if they were admitted and continued therapy as an inpatient during the study period.
Data Collection, Study Definitions, and Assessment of AEs
Data were extracted from electronic health records and collected using REDCap electronic data-capture tools hosted at our institution [20] . Two ID-trained physicians (A. D. and M. V. K.) conducted independent chart reviews to obtain information on patient demographics, chronic conditions, and details of moxifloxacin use and to identify AEs using prespecified criteria (detailed later). To classify current or past chronic conditions, we used the Agency for Healthcare Research and Quality Chronic Condition Indicator (CCI) system, which categorizes conditions as chronic or acute and places each condition into 1 of 18 mutually exclusive categories (organ systems, disease categories, or other categories) [21] . We reassigned to organ-specific categories certain diagnoses that involve stem cell or solid organ transplantation that are classified by the CCI system in the category "factors influencing health status and contact with health services. " We excluded the category "complications of pregnancy, childbirth, and the puerperium" because none of the participants had a condition in this category and obstetric care is not provided at our institution. Discrepancies between reviewers were assessed by the authors (A. D., M. V. K., and M. M. N.) and resolved via consensus. Attribution of AEs to moxifloxacin use was adjudicated in consultation with a pediatric ID pharmacist (S. J.).
Our primary unit of analysis was a course of moxifloxacin, defined as ≥1 consecutive days of treatment. On the basis of the half-life of moxifloxacin, >97% of the drug is eliminated within 3 days of a dose; we therefore analyzed periods of therapy separated by a gap of >3 days as separate courses. We recorded the number of concomitant medications, defined as a systemic drug listed as a "scheduled medication" at the time of the first moxifloxacin dose. ID consultation for moxifloxacin use was identified on the basis of the presence of a formal consultation note; notation of a "curbside" discussion with a member of the ID service was not considered an ID consultation. AEs were determined on the basis of a review of clinical notes, laboratory results, and electrocardiography (ECG) results. Laboratory or ECG values obtained ≤1 week before the first dose of moxifloxacin were considered the baseline values for each course. AEs that occurred during the course and ≤3 days after moxifloxacin discontinuation were reviewed. Attribution of an AE was determined first by documentation in the medical record by a treating provider at the time of the AE. If no such attribution was documented, then laboratory abnormalities were identified by using predefined reference values from the Harriet Lane Handbook [22] (Appendix 1). AEs identified during the moxifloxacin course that began before initiation of the drug were attributed to another drug or underlying condition, as appropriate. If an AE occurred after moxifloxacin initiation and improved after discontinuation, it was attributed to moxifloxacin. AEs for which attribution was uncertain on initial review were reviewed further by a pediatric ID pharmacist (S. J.) and resolved using an approach adapted from the Naranjo scale [23] , a standardized scale for assessing adverse drug reaction causality in which those AEs under the "probable" or "definite" categories were attributed to moxifloxacin and the rest remained attributed as uncertain (Appendix 2).
Statistical Analyses
Data were analyzed using R 3.3.2 [24] , including the eeptools package [25] age_calc() function to calculate age at the time of moxifloxacin administration using date of birth, and Stata 13 [26] . Statistical significance was determined at the 5% level using 2-sided P values. The χ 2 test was used to compare variables in univariate analysis, and the Wilcoxon rank-sum test was used to test the association between duration of therapy and the occurrence of AEs. Interrater agreement was calculated by using a randomly selected subset of courses using the irr package [27] for R. To assess relationships between patient and moxifloxacin-course characteristics and the risk of AEs attributed to moxifloxacin use, we used multivariable logistic regression using generalized estimating equations to account for multiple courses of moxifloxacin (ie, repeated measures) in the same patient. We also used multivariable logistic regression to investigate the associations between patients and moxifloxacin-course characteristics and the specific outcome of QTc prolongation among patients who underwent ECG at least once during their moxifloxacin course.
RESULTS
Demographic Data
Of the 221 patients who met the inclusion criteria (Table 1) , 1 patient was excluded from further analysis because of incomplete records. A total of 300 moxifloxacin courses were initiated during the study period (Table 2) . Fever, including febrile neutropenia, was the most common reason for admission (87 [29%] of 300 courses). Among patients with a chronic condition (n = 198), neoplasms were the most common (69 [34.8%]), followed by disorders of the nervous system and sense organs (64 [32.3%]).
Moxifloxacin-Course Characteristics
Characteristics of the 300 moxifloxacin courses are shown in Table 2 . The average duration of therapy was 3 weeks. The average dose prescribed (10.17 mg/kg for patients who weighed <40 kg and 398.3 mg for those who weighed ≥40 kg) was consistent with the dosing recommended by the World Health Organization [28] . The first dose for a majority of the courses (177 [59%]) was administered in a non-intensive care inpatient ward, 
AEs and Monitoring
Among all 300 courses, 463 total AEs in 195 courses occurred; 46 (9.9%) AEs that occurred in 43 (14.3%) courses were attributed to moxifloxacin ( Table 3 ). The frequencies and attributions of AEs according to organ system are shown in Figure 1 . The frequencies of laboratory and ECG monitoring at baseline and during therapy are listed in Table 4 . The majority of patients had complete blood counts (CBCs) and transaminase level measurements, but not ECG, performed at baseline and during therapy. We found no differences in age, sex, or chronic conditions between patients who underwent ECG monitoring during moxifloxacin therapy and those who did not, but the average number of concomitant medications was higher in those who underwent ECG monitoring than those who did not (9.8 vs 7.8, respectively; P = 0.008). Among courses with no AEs (n = 105), the average treatment duration was 19.5 days (range, 1-295 days); among courses with AEs (n = 195), the average treatment duration was 23.2 days (range, 1-590 days). We found no association between duration of therapy and occurrence of any AEs (P = .57).
The most common AEs attributable to moxifloxacin were QTc prolongation (in 18 [6%] courses), transaminase elevation (8 [2.7%]), and elevation of bilirubin levels (3 [1%] ). Among the 8 courses during which transaminase elevation occurred, the mean aspartate transaminase (AST) level was 295.5 U/liter (range, 96-807 U/liter), and the mean alanine transaminase (ALT) level was 275 U/liter (range, 114-805 U/liter).
Age-specific QTc prolongation was observed in 18 courses (6% [21%] of the 85 courses during which ECG was performed during therapy). Prolongation was detected a mean of 11 days (range, 1-62 days; interquartile range, 3.25-12 days) after moxifloxacin initiation. The mean The total number of courses was 300.
b Excludes 1 patient who remained on moxifloxacin at the end of the study period. Three patients underwent a long course (590, 540, and 372 days) for treatment of disseminated Mycobacterium bovis bacillus Calmette-Guérin infection before, during, and after undergoing stem cell transplantation. c Weight-based dosing (10 mg/kg of body weight) is recommended for patients who weigh <40 kg. For those who weigh ≥40 kg, a standard dose of 400 mg is recommended. One patient received 19.32 mg/kg per dose daily for 2 doses, after which the dose was decreased to 10 mg/ kg per dose daily for the remainder of the course. e Premature discontinuation was defined as discontinuation of moxifloxacin before the predetermined duration of treatment decided at the initiation of therapy.
prolonged QTc measurement was 479.5 msec (range, 450-541 msec). The mean age of patients with prolonged QTc was 12.56 years (range, 7-17.9 years). Concomitant QTc-prolonging agents were administered in 10 courses: voriconazole (3), proton-pump inhibitors (PPIs) (2), both fluconazole and a PPI (2), both escitalopram and a PPI (1), haloperidol (1), and ondansetron (1). In 4 courses, the QTc prolongation was transient, and the interval returned to normal despite the continuation of moxifloxacin. Moxifloxacin was continued in 7 courses despite QTc prolongation, and no clinical sequelae were reported. QTc prolongation led to discontinuation of moxifloxacin therapy in 5 courses. In 1 course, moxifloxacin was discontinued because of isolation of a moxifloxacin-resistant organism rather than the QTc prolongation. QTc prolongation did not recur with a subsequent course in this patient. In 1 course, prolongation was noticed the day after discontinuation of moxifloxacin, but it eventually resolved.
Serious AEs Attributed to Moxifloxacin
Two occurrences of leukopenia were attributed to moxifloxacin. The patients were on concomitant medications (vancomycin in 1 case, levetiracetam in the other case) and developed an absolute neutrophil count nadir of 70 and 42 cells/µL, respectively, which recovered after moxifloxacin discontinuation.
Two occurrences of seizures were attributed to moxifloxacin. Both patients had an underlying seizure disorder, and out of concern that moxifloxacin contributed to a decreased seizure threshold, the treating physicians discontinued moxifloxacin in 1 case and decreased the dose in the other case. Two cases of peripheral neuropathy were documented, 1 of which was attributed to moxifloxacin. The other was attributed to linezolid by the treating physician on the basis of the timing and improvement of symptoms after discontinuation of linezolid. Both cases of peripheral neuropathy proved to be reversible after discontinuation of the offending drug.
Risk Factors for AEs
In multivariable regression analysis incorporating age, sex, race, type of underlying chronic condition(s), number of allergies, and duration of moxifloxacin therapy, the number of concomitant scheduled medications and the number of antibiotic allergies were significantly associated with the occurrence of AEs attributed to moxifloxacin (Table 5 ). When we analyzed the specific outcome of QTc prolongation in the 85 courses in patients who underwent ECG at least once during moxifloxacin therapy, we found that increasing age, African/ African American race, and the number of concomitant scheduled medications were significantly associated with QTc prolongation, after we adjusted for sex, type of underlying chronic condition(s), number of allergies, and duration of moxifloxacin therapy (Table 6 ). The total number of courses was 300.
Pediatric ID Consultation
The pediatric ID service performed a formal consultation for 140 (46.7%) of the 300 moxifloxacin courses. Among patients <12 years of age (n = 180), the pediatric ID service performed a formal consultation for 87 (48%) courses. Involvement of the ID service was significantly associated (compared with those for whom the ID service was not involved) with ECG (64% vs 29%, respectively; P < .001) and hepatic transaminase (79% vs 63%, respectively; P = .002) monitoring but not with CBC (94% vs 93%, respectively; P = .87) or bilirubin (77% vs 68%, respectively; P = .1) monitoring.
Effect of Restriction Under the ASP
Among the courses administered to patients aged <12 years (n = 180), 48 (27%) courses were given after restriction of the drug (ie, requirement for an ID consultation) in that age group began in September 2013; a formal ID consultation was performed for 83% of those 48 courses. How moxifloxacin was administered without an ID consultation in the remaining 17% cases was unclear.
One possible explanation is that if a patient received moxifloxacin overnight in the ED and was subsequently discharged, no opportunity for a formal ID consultation would have arisen.
The percentage of moxifloxacin courses used for empiric therapy decreased significantly after the drug's restriction under the ASP, not just in patients aged <12 years (54% vs 10%, respectively; P < .001), in whom the restriction was applicable, but also overall (47% vs 14%, respectively; P < .001). Restriction also correlated with increased QTc monitoring, both in patients aged <12 years (33% vs 73%, respectively; P = .002) and overall (40% vs 60%, respectively; P = .002). Restriction was not associated with a statistically significant change in monitoring of the CBC or transaminase or bilirubin levels.
Interrater Agreement
The 2 chart reviewers (A. D. and M. V. K.) both reviewed charts for a randomly selected subset of 32 courses. The Cohen κ value for the occurrence of an AE and cause of an AE were 0.7 and 0.66, respectively, results that fall within the range for substantial agreement between raters [29] .
DISCUSSION
This retrospective chart review of 300 moxifloxacin courses in 220 children revealed that the antibiotic was generally safe and well tolerated and resulted in a low overall rate of moxifloxacin-associated AEs (14.3% of all courses). We found that QTc prolongation was the most common AE attributed to moxifloxacin, followed by transaminase elevation, both of which are recognized effects of fluoroquinolones [30, 31] . Consultation by the pediatric ID service was significantly associated with reduced use of moxifloxacin for empiric therapy and increased performance of both QTc and transaminase monitoring, which highlights the importance of expert consultation for guiding judicious and safe use. In multivariable analysis, the number of concomitant medications and number of allergies were associated with an increased risk of AEs attributed to moxifloxacin use. Use of a large number of concomitant medications might independently lead to AEs and also can indicate medical complexity that could be associated with a greater risk for AEs. An increased intensity of monitoring for patients with these characteristics might be warranted.
With regard to the outcome of QTc prolongation, the number of concomitant medications again was a significant risk factor, as was older age and African/African American race. Most patients with QTc prolongation were also taking other QTc-prolonging medications. However, patients on concomitant medications were more likely also to have undergone ECG during therapy. Higher age as a risk factor possibly reflects the inherent increase in QTc with age, as reflected in higher normal QTc cutoffs for older children [22] . It is notable also that the rate of QTc prolongation in our study (6% of all courses, 21% of the 85 courses with ECG performed during therapy) was higher than that seen in adults (<2%) [32] . No studies on race/ethnicity-related differences in QTc in children have been performed. In more than half of the courses in which QTc prolongation occurred, the patients were taking another QTcprolonging medication in addition to moxifloxacin. Additional research is needed to characterize the magnitude of risk in patients receiving other QTc-prolonging medications and moxifloxacin together; such patients might need more intensive ECG monitoring or consideration of alternative antibiotic options when possible. No clinical cardiac events were seen in our study; however, because QTc prolongation is associated with an increased risk for potentially life-threating AEs, ECG monitoring should be performed at baseline and during therapy in patients receiving moxifloxacin. In our study, the average time to QTc prolongation was approximately 10 days; on the basis of this finding, performing pre-therapy ECG followed by repeat ECG 7 to 10 days into moxifloxacin therapy would be a reasonable monitoring approach. For those patients in whom QTc prolongation is detected or who are receiving concomitant QTc-prolonging drugs, further periodic ECG monitoring seems prudent.
Increased transaminase levels were the second most common moxifloxacin-related AE; this effect has been recognized as a class effect of fluoroquinolones [31] . Hepatotoxicity caused by fluoroquinolones has been found to occur abruptly soon after drug initiation [31] . The patterns of injury can vary; There were no patients in the race category "Asian" in whom ECG monitoring was performed during moxifloxacin therapy. The reference group for each chronic condition indicator variable is no chronic condition in that category.
hepatocellular, cholestatic, and mixed patterns have been reported [31] . Although the exact pathophysiology is unknown, some evidence exists to suggest that injury occurs via a hypersensitivity reaction [31] . The results of our study contribute to evidence supporting the inclusion of transaminase and bilirubin level measurements in moxifloxacin monitoring. An important finding of our study was the effect of ASP restriction (in the form of mandatory ID consultation for patients aged <12 years) on AE monitoring. For moxifloxacin therapy courses of >2 weeks, our pediatric ID service typically recommends ECG, a CBC with differential, and transaminase levels (not including bilirubin) measurement at baseline and approximately 1 week into therapy; additional monitoring should be determined by findings of the patient's initial monitoring, the patient's underlying risk factors for AEs, and anticipated duration of treatment. ID consultation was significantly associated with QTc and transaminase monitoring, likely because of the recommendations offered by the ID service. However, this effect was not found for CBC monitoring, probably because this test was commonly ordered for other reasons both before and during therapy with moxifloxacin, or for bilirubin monitoring, which is not included in the ID service's recommendations. The benefits of ID consultation have been shown previously. For example, in a prospective cohort study of patients with Staphylococcus aureus bacteremia, ID consultation was associated with a 56% reduction in the 28-day mortality rate [33] . However, in another prospective study of outcomes associated with ID consultation, the in-hospital mortality rates were not significantly different for patients when the requesting service either adhered or did not adhere to the consultants' diagnostic or monitoring recommendations [34] . We are unaware of any previous studies that examined the effect of such recommendations on patient morbidity.
After restriction under our ASP, the percentage of moxifloxacin courses that were prescribed for empiric therapy declined significantly, as did use of the drug in the age group subject to restriction. In keeping with our findings, a meta-analysis revealed that the implementation of an ASP is associated with a decreased use of broad-spectrum antibiotics [35] . Given its broad-spectrum coverage, moxifloxacin for empiric therapy might be appealing to clinicians. However, because of FDA warnings and the paucity of pediatric safety data [13] , such use should be minimized.
To our knowledge, this is the largest study to date to have evaluated the safety and tolerability of moxifloxacin in children. The rate of AEs in our study was lower than the 16% rate reported with pediatric use of fluoroquinolones in a physician survey in France and the 29% rate found in a postmarketing survey of pediatric ciprofloxacin use [36, 37] . In 2 previous studies with smaller sample sizes, moxifloxacin was found to be safe in children with tuberculosis, including those with multidrug-resistant tuberculosis [38, 39] . In keeping with our findings, hepatotoxicity was noted in both studies, but interesting to note is that no instances of QTc prolongation were seen (ECG results were monitored in all patients in 1 study and in almost half of the patients in the other study). In contrast with our study, all patients received moxifloxacin as part of an antituberculosis multidrug regimen, and fewer patients might have had predisposing conditions or been taking concomitant QTcprolonging medications. In addition, a pooled analysis of phase II to IV clinical trials revealed no increased risk of clinical cardiac AEs in adults receiving moxifloxacin over that with other antimicrobial agents [40] . Although musculoskeletal AEs were reported in both of the other pediatric studies, we observed none in our study. This finding is reassuring although we were unable to capture events not reported or not documented in the patient's medical record. Providers should continue to counsel patients regarding this AE.
We acknowledge certain limitations of our study. Because our study inclusion criteria required receipt of at least 1 dose of moxifloxacin while hospitalized or in the ED, data from patients who received their entire course of moxifloxacin on an outpatient basis were not captured in our study. Laboratory and ECG monitoring was not performed for all patients, which possibly led to an underestimation of the frequency of AEs. ECG monitoring was performed during only 85 (28.3%) courses of moxifloxacin therapy, which limited our power to identify risk factors for QTc prolongation. In addition, the absence of baseline ECG data in some cases prevented us from determining whether QTc prolongation was preexisting or a new finding after moxifloxacin initiation. Symptoms that can be difficult for young children to express, such as tingling or numbness, might not have been reported during follow-up. In addition, AEs were identified retrospectively by chart review of clinician notes and laboratory results. Therefore, we would not have captured events not documented in the chart. Our patient population comprised many children with complex medical conditions, so these results might not be generalizable to healthy children. However, we suspect that this limitation would result in an overestimation rather than an underestimation of the frequency and severity of moxifloxacin-associated AEs, because children with complex conditions would be more likely to develop AEs as a result of their underlying health status and need for concomitant medications. Lastly, the attribution of AEs was based on expert assessment guided by an objective scale [23] , but because our study was retrospective, the potential for misattribution still exists. Future research is needed to characterize the safety and risks of moxifloxacin prospectively in children.
CONCLUSIONS
Our findings suggest that moxifloxacin is generally well tolerated in children and that related AEs rarely lead to the discontinuation of therapy. QTc prolongation is an important AE for which monitoring is not performed routinely during therapy. The guidance of a pediatric ID specialist is key for encouraging judicious use and appropriate AE monitoring.
Notes
